Replicate Bioscience
Replicate Bioscience is a clinical-stage San Diego biotech developing self-replicating RNA (srRNA) vaccines and therapeutics for infectious disease, oncology, and autoimmune indications, monetizing its platform through enterprise pharma partnerships (notably Novo Nordisk), regional commercialization deals (Instituto Butantan), and Gates Foundation grants.
- Company typePrivate
- Founded2014
- HeadquartersSan Diego, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Replicate Bioscience does
Replicate Bioscience is a clinical-stage biotechnology company developing self-replicating RNA (srRNA) therapeutics and vaccines. Its proprietary srRNA platform uses synthetic vectors that, once inside a cell, direct the cell's own machinery to produce multiple copies of a target mRNA, yielding approximately 1,000-fold greater protein expression than linear mRNA and approximately 100-fold greater than first-generation srRNA, with bioactivity demonstrated at doses as low as 0.1 micrograms. The platform underpins a diversified pipeline: a Phase 1-completed rabies vaccine (RBI-4000) with WHO-threshold protection and 6-month durability data published in Nature Communications and Communications Medicine; wholly owned infectious disease vaccines for RSV/hMPV/PIV (RBI-6000) and Epstein-Barr virus (RBI-5000); precision immuno-oncology programs in ER+ breast cancer (RBI-1000) and EGFR-mutant NSCLC (RBI-3000); and protein-replacement therapeutics including a gout candidate (RBI-8000) and undisclosed cardiometabolic targets (RBI-X000).
The company's business model is partnership-driven rather than commercial: it does not sell approved products and operates as a clinical-stage platform. Revenue and funding are generated through enterprise pharma collaborations, non-dilutive grants, and equity financing. The centerpiece is a multi-year collaboration with Novo Nordisk granting worldwide exclusive cardiometabolic rights to the srRNA platform, with up to ~$550 million in upfront, research, and milestone payments plus tiered royalties. A December 2025 agreement with Instituto Butantan grants exclusive Latin American rights to RBI-4000, with Butantan funding registrational trials. Non-dilutive capital has come from three Gates Foundation grants totaling approximately $10 million for HIV, malaria, and tuberculosis vaccines under humanitarian licensing terms, and $46 million in equity from Apple Tree Partners (Series 1 of $6M in February 2021 and Series A of $40M in September 2021). Manufacturing and delivery are enabled through supporting collaborations with Curia (CDMO) and Precision NanoSystems (LNP and microfluidic formulation). Replicate is headquartered in San Diego, California, employs 11–50 people, and is a portfolio company of Apple Tree Partners.
Replicate Bioscience firmographics
Firmographics- Name
- Replicate Bioscience
- Legal name
- Replicate Bioscience, Inc.
- Website
- https://replicatebioscience.com
- Company type
- Private
- Founded year
- 2014
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Replicate Bioscience is a clinical-stage San Diego biotech developing self-replicating RNA (srRNA) vaccines and therapeutics for infectious disease, oncology, and autoimmune indications, monetizing its platform through enterprise pharma partnerships (notably Novo Nordisk), regional commercialization deals (Instituto Butantan), and Gates Foundation grants.
- Ownership category
- akta.pro rank
Replicate Bioscience industry classification
Industry- Product category
- RNA Therapeutics and Vaccines
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- mRNA Therapeutics (vaccines, protein replacement, immuno-oncology) (HLAAADAA)
- akta.pro secondary industries
- Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA) (HLAAAEAD), Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies) (HLAAANAK), Plasmid DNA & mRNA Manufacturing Services (HLAAAKAE), RNA Therapeutics Clinical Development (trial design, endpoints, patient stratification) (HLAAADAH)
Keywords
Where Replicate Bioscience is headquartered
LocationHeadquarters
- HQ city
- San Diego
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Replicate Bioscience business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Research funding and milestone payments: Partnerships with pharmaceutical companies providing upfront payments, research funding, and milestone-based payments for development success. Includes the Novo Nordisk partnership worth up to $550 million in research funding and milestone payments.
- Royalty arrangements: Tiered royalties on future product sales from commercialization agreements, such as the Instituto Butantan partnership for Latin American rabies vaccine commercialization.
- Grant funding: Non-dilutive funding from the Gates Foundation for global health vaccine development including tuberculosis ($3M), HIV ($3.5M), and malaria ($3.5M) vaccine programs.
- Series A funding: Venture capital funding ($40M Series A from Apple Tree Partners) to advance multiple srRNA programs into clinical development.
Go-to-market motion2 records
Distribution channels2 records
Marketing channels4 records
Replicate Bioscience product offering
Product offeringCore offering
Replicate Bioscience develops and licenses a proprietary next-generation self-replicating RNA (srRNA) technology platform that programs cells to repeatedly produce therapeutic proteins at roughly 1000-fold higher expression than linear mRNA, enabling vaccines and immunotherapies at dramatically lower doses. The company is advancing a clinical-stage pipeline of srRNA vaccines (rabies, RSV/hMPV/PIV, EBV), precision immuno-oncology candidates (ER+ breast cancer, EGFRm+ NSCLC), and protein-replacement therapeutics (gout, cardiometabolic disease) primarily through enterprise partnerships with pharmaceutical and global health organizations.
Product overview
Replicate Bioscience is a clinical-stage biotechnology company pioneering a proprietary self-replicating RNA (srRNA) technology platform. The platform enables cells to produce their own therapeutic proteins through self-limited replication, achieving approximately 1000-fold expression gain over linear mRNA and 100-fold gain over standard srRNA. The company is advancing a pipeline of srRNA-based vaccines and immunotherapies spanning infectious disease (RBI-4000 for rabies, RBI-6000 for RSV/hMPV/PIV, RBI-5000 for infectious mononucleosis), precision immuno-oncology (RBI-1000 for ER+ breast cancer, RBI-3000 for EGFRm+ NSCLC), and protein drug replacement therapeutics (RBI-8000 for gout, RBI-X000 for cardiometabolic diseases). The srRNA platform is enhanced by a customizable library of synthetic viral vectors, optimized protein inserts, validated delivery systems, and strategic manufacturing collaborations.
Differentiator
Problem solved
Functional benefit
Products and services
- RBI-4000 Clinical-stage self-replicating RNA (srRNA) vaccine candidate for rabies prevention encoding the viral glycoprotein; demonstrated protective immunity at doses as low as 0.1 mcg with WHO threshold for protection achieved at all dose levels in Phase 1, and 100% of participants retaining detectable rabies virus neutralizing antibodies at 6 months.
- RBI-6000 Wholly owned srRNA vaccine candidate targeting respiratory syncytial virus (RSV), human metapneumovirus (hMPV), and parainfluenza virus (PIV) with multiple antigens encoded on the srRNA vector.
- RBI-5000 Wholly owned srRNA vaccine candidate for infectious mononucleosis caused by Epstein-Barr virus, targeting multiple antigens via the srRNA platform.
- RBI-8000 srRNA therapeutic candidate for chronic refractory gout and expansion on proof of concept, targeting pan-inflammasome inhibition through an IL-1 receptor agonist and IL-18 binding protein mechanism; part of the Novo Nordisk cardiometabolic partnership.
- RBI-X000 srRNA therapeutic program for obesity, type 2 diabetes, and other cardiometabolic diseases with an undisclosed mechanism, developed under the multi-year Novo Nordisk collaboration worth up to $550 million in research funding and milestones plus tiered royalties.
- RBI-1000 First-in-class srRNA precision immunotherapy for ER+ breast cancer targeting endocrine therapy resistance mutations via a synthetic immune lethality mechanism combining standard of care with srRNA-trained immune cells; IND-enabling studies ongoing.
- RBI-3000 srRNA precision immunotherapy candidate targeting acquired resistance to tyrosine kinase inhibitor standard of care therapy for metastatic EGFRm+ non-small cell lung cancer.
- RBI-2000 Research-stage srRNA candidate encoding two distinct biotherapeutic proteins on a single vector backbone for therapeutic protein delivery; demonstrated tumor control in a preclinical MC38 murine tumor model as proof of concept for multi-protein srRNA expression.
Quantifiable outcome
- Therapeutic index >100-fold demonstrated clinically with RBI-4000, compared to 1-10-fold for linear mRNA and first-generation srRNA
- +4 more outcomes
Companies that use Replicate Bioscience
Customer profileNamed customers1 record
Segments3 records
Ideal customer profiles3 records
Replicate Bioscience technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Replicate Bioscience partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered core and supporting.
- Bill & Melinda Gates FoundationcoreThird research grant of approximately $3 million to advance srRNA vaccine candidates for tuberculosis. Grant subject to humanitarian licensing terms for global health applications in underserved populations. Builds on previous Gates Foundation grants for HIV and malaria vaccine development.
- Bill & Melinda Gates FoundationcoreApproximately $7 million in combined funding for development of srRNA vaccines targeting HIV (~$3.5M) and malaria (~$3.5M). Grants subject to humanitarian licensing terms addressing two of the world's most persistent public health burdens.
- Instituto ButantancoreCollaboration to develop and commercialize Replicate's srRNA rabies vaccine RBI-4000 in Latin America. Instituto Butantan will conduct registrational clinical trials in Brazil and Latin America, fund development, and obtain manufacturing rights. Replicate retains rights for development in markets outside Latin America and receives tiered royalties on future sales.
- Novo NordiskcoreMulti-year research collaboration to develop novel srRNA therapies for obesity, type 2 diabetes, and other cardiometabolic diseases. Novo Nordisk receives exclusive worldwide license to use Replicate's srRNA platform for lead programs. Replicate eligible for up to $550 million in research funding, milestone payments, and tiered royalties on future product sales.
- Precision NanoSystemssupportingLicensing deal to scale up genomic medicines. Precision NanoSystems provides access to proprietary LNP delivery systems and microfluidic formulation platform technology.
- CuriasupportingStrategic collaboration to create a groundbreaking development platform for self-replicating RNA (srRNA). Curia provides contract development and manufacturing services to support Replicate's srRNA platform.
Scale indicators4 records
Recent moves6 records
Expansion highlights6 records
Replicate Bioscience competitors and assessment
Company assessmentDirect peers
- Arcturus Therapeutics: Arcturus develops self-amplifying mRNA (saRNA) therapeutics and vaccines using the LUNAR delivery platform, the closest direct competitor to Replicate's srRNA technology. Both companies target infectious-disease vaccines and rare/liver diseases with self-replicating RNA constructs, and both have advanced clinical assets (Arcturus: CSL-partnered saRNA influenza vaccine approved/filed).
- Strand Therapeutics: Strand is a programmable self-replicating mRNA company focused on oncology and autoimmune disease, directly comparable to Replicate's PIO (precision immuno-oncology) programs RBI-1000 and RBI-3000. Both companies use srRNA as a multi-gene delivery vehicle for cancer and immune indications, competing for the same partner and investor mindshare.
- Sail Biomedicines: Sail (formerly Laronde) develops endless RNA (eRNA), a circular, self-replicating RNA platform intended for long-duration protein expression. Although structurally distinct from Replicate's srRNA vectors, Sail targets the same fundamental opportunity — durable, low-dose RNA therapeutics — and competes head-to-head with Replicate in pharma partnering discussions.
Broad incumbents
- Moderna: Moderna is the dominant mRNA vaccines and therapeutics company with multiple approved products (Spikevax) and a broad pipeline spanning infectious disease, oncology, and rare disease. While Replicate's srRNA is differentiated, Moderna is actively advancing self-amplifying mRNA candidates and is the most consequential incumbent competitor in the RNA modality.
- BioNTech: BioNTech is a leading mRNA therapeutics company with deep expertise in cancer vaccines and infectious-disease vaccines, anchored by the Pfizer-partnered Comirnaty franchise. BioNTech's pipeline scope, manufacturing scale, and immuno-oncology focus make it a broad incumbent against Replicate's PIO programs.
- CureVac: CureVac is an early mRNA vaccines and therapeutics company developing optimized mRNA constructs for cancer, prophylactic vaccines, and molecular therapy. Although historically focused on linear mRNA, CureVac has invested in next-generation constructs and competes for the same infectious-disease and oncology partnering opportunities as Replicate.
- Pfizer: Pfizer is a global pharmaceutical incumbent that has invested heavily in mRNA through its partnership with BioNTech and internal RNA programs. Pfizer's prior acquisition of Replicate's predecessor srRNA assets (via the 2019 Janssen/Synthetic Genomics transaction) makes it a particularly relevant incumbent comparator in cardiometabolic and infectious-disease RNA.
- Sanofi (Translate Bio): Sanofi acquired Translate Bio in 2021 and continues to develop mRNA vaccines and therapeutics internally. Sanofi's large infectious-disease and cardiometabolic franchises make it a relevant incumbent comparator, and a potential future partner or competitor for Replicate's srRNA programs.
Emerging players
- Vir Biotechnology: Vir is a clinical-stage immunology company developing infectious-disease therapeutics with a particular focus on vaccines and monoclonal antibodies. Vir's infectious-disease focus and large-pharma partnerships make it an emerging competitor in the global-health vaccine space where Replicate is most active.
- Tessera Therapeutics: Tessera is developing RNA-based 'gene writing' therapeutics that, while distinct from srRNA, compete in the broader therapeutic modality landscape for in-vivo production of therapeutic proteins. Tessera's emerging gene-writing platform is an adjacent, enabling comparator relevant to Replicate's protein-replacement programs in cardiometabolic disease and gout.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
Replicate Bioscience social profiles
Digital presenceReplicate Bioscience financial estimates
Financial estimateRevenue estimate
Valuation estimate
Replicate Bioscience leadership team
Management profileNumber of profiles
Profiles8 records
Replicate Bioscience funding detail
Funding detailFunding overview
Funding rounds4 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Replicate Bioscience M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Replicate Bioscience
What does Replicate Bioscience do?
Replicate Bioscience develops and licenses a proprietary next-generation self-replicating RNA (srRNA) technology platform that programs cells to repeatedly produce therapeutic proteins at roughly 1000-fold higher expression than linear mRNA, enabling vaccines and immunotherapies at dramatically lower doses. The company is advancing a clinical-stage pipeline of srRNA vaccines (rabies, RSV/hMPV/PIV, EBV), precision immuno-oncology candidates (ER+ breast cancer, EGFRm+ NSCLC), and protein-replacement therapeutics (gout, cardiometabolic disease) primarily through enterprise partnerships with pharmaceutical and global health organizations.
Is Replicate Bioscience a public or private company?
Replicate Bioscience is a private company. It is classified as venture growth investor backed and is currently operating.
When was Replicate Bioscience founded?
Replicate Bioscience was founded in 2014. It employs 11 to 50 people.
Where is Replicate Bioscience based?
Replicate Bioscience is headquartered in San Diego, United States, in the North America region.
How does Replicate Bioscience make money?
Four revenue lines are on record. Research funding and milestone payments are the primary driver. The others are royalty arrangements, grant funding and series A funding.
Who are Replicate Bioscience's main competitors?
Direct peers on record are Arcturus Therapeutics, Strand Therapeutics and Sail Biomedicines. Broad incumbents are Moderna, BioNTech, CureVac, Pfizer and Sanofi (Translate Bio). Emerging players are Vir Biotechnology and Tessera Therapeutics.
Does Replicate Bioscience have an API?
No public API is recorded for Replicate Bioscience.
What industry is Replicate Bioscience in?
Replicate Bioscience's product category is RNA Therapeutics and Vaccines. Its primary akta.pro industry code is HLAAADAA, mRNA Therapeutics (vaccines, protein replacement, immuno-oncology), with a secondary code of HLAAAEAD, Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA). Its NAICS code is 325414 and its SIC code is 2836.